PCP
ONCT

Proficio Capital Partners’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Proficio Capital Partners’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-33
Closed -$4K – 1673
2019
Q2 		$4K Hold
33
– – ﹤0.01% 1334
2019
Q1 		$5K Buy
+33
New +$4.92K ﹤0.01% 1128

Other funds holding ONCT

Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
DY
Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Proficio Capital Partners's ONCT Position: Q3 2019 in Review

Proficio Capital Partners sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2019, closing a stake of 33 shares — an estimated $4K sold.

Proficio Capital Partners first reported a position in ONCT in Q1 2019 and held it in 2 quarters. The position peaked at $5K in Q1 2019. 25 funds tracked by Wall St. Rank hold ONCT as of Q3 2019.

  • Proficio Capital Partners reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 33 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $4K.
  • Proficio Capital Partners first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • Proficio Capital Partners's Oncternal Therapeutics, Inc. Common Stock position peaked at $5K in Q1 2019.
  • 25 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.